Recruiting Phase 1 2025-523845-90-00

Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

Phase 1 – testing safety in a small group of people

Conditions: Relapsed/Refractory Hematologic Autoimmune Disease

Sponsor: CRISPR Therapeutics AG

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 45 participants

Germany (1)

Spain (1)

Status

Recruiting

Phase

Phase 1

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Healthy volunteers

Start date

12.03.2026

Registry ID

2025-523845-90-00

Source

euclinicaltrials.eu

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.